Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Antiviral Effect of ABT-450/Ritonavir and ABT-530 Coadministered With and Without Ribavirin in Adults With Genotype 3 Hepatitis C (HCV) Infection

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female (of non-child bearing potential) between 18 and 70 years of age with Body Mass Index ≥18 to \<38 kg/m2.~* Chronic HCV genotype 3 infection prior to study enrollment and has never received antiviral treatment for HCV.~* Subject has plasma HCV RNA level \> 10,000 IU/mL at Screening.~* Sexually active males must be sterile, have male partners only, or agree to use two effective forms of birth control for 7 months after stopping study drug.~Exclusion Criteria:~* History of severe, life-threatening or other significant sensitivity to any drug.~* Positive test result for Hepatitis B surface antigen (HBsAg) or anti-Human Immunodeficiency virus antibody (HIV Ab).~* Prior therapy for the treatment of HCV.~* Any current or past clinical evidence of cirrhosis.~* Any cause of liver disease other than chronic HCV-infection.~* HCV genotype co-infection with any other HCV genotype.~* Use of contraindicated medications within 2 weeks or 10 half-lives of dosing.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- ABT-450/r and ABT-530 plus RBV (Type: EXPERIMENTAL): ABT-450/r (150 mg/100 mg) once daily (QD) co-administered with ABT-530 (120 mg) once daily (QD) plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).